KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

AbCellera Biologics (ABCL) Net Margin: 2020-2023

Historic Net Margin for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -513.67%.

  • AbCellera Biologics' Net Margin fell 37493.00% to -513.67% in Q4 2023 from the same period last year, while for Dec 2023 it was -384.99%, marking a year-over-year decrease of 41765.00%. This contributed to the annual value of -564.83% for FY2024, which is 17982.00% down from last year.
  • AbCellera Biologics' Net Margin amounted to -513.67% in Q4 2023, which was down 18.48% from -433.55% recorded in Q3 2023.
  • AbCellera Biologics' Net Margin's 5-year high stood at 59.70% during Q2 2020, with a 5-year trough of -513.67% in Q4 2023.
  • Over the past 3 years, AbCellera Biologics' median Net Margin value was -76.76% (recorded in 2022), while the average stood at -162.46%.
  • Its Net Margin has fluctuated over the past 5 years, first surged by 41,442bps in 2022, then crashed by 45,981bps in 2023.
  • Quarterly analysis of 4 years shows AbCellera Biologics' Net Margin stood at 56.28% in 2020, then plummeted by 1,325bps to 43.03% in 2021, then slumped by 18,177bps to -138.75% in 2022, then tumbled by 37,493bps to -513.67% in 2023.
  • Its last three reported values are -513.67% in Q4 2023, -433.55% for Q3 2023, and -303.58% during Q2 2023.